Date:2/8/2011

ty to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:Investors:

Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia:

Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

'/>"/>

SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
3. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
6. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
7. Savient Pharmaceuticals Provides Business Update
8. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Anadys Pharmaceuticals Augments Management Team and Board of Directors
10. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
11. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference